Evidence map›Paper›PMID 31512141›Full record

ArticleAdvances in therapy2019

Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8.

Omar Dabbous, Benit Maru, Jeroen P Jansen, Maria Lorenzi, Martin Cloutier, Annie Guérin, Irina Pivneva, Eric Q Wu, Ramesh Arjunji, Douglas Feltner and 1 more

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Omar DabbousAveXis, Inc, Bannockburn, IL, USA.
Benit MaruAveXis, Inc, Bannockburn, IL, USA.
Jeroen P JansenPrecision Xtract, Oakland, CA, USA.
Maria LorenziPrecision Xtract, Oakland, CA, USA.
Martin CloutierAnalysis Group, Inc, Montreal, QC, Canada.
Annie GuérinAnalysis Group, Inc, Montreal, QC, Canada.
Irina PivnevaAnalysis Group, Inc, Montreal, QC, Canada.
Eric Q WuAnalysis Group, Inc, Boston, MA, USA.
Ramesh ArjunjiAveXis, Inc, Bannockburn, IL, USA.
Douglas FeltnerAveXis, Inc, Bannockburn, IL, USA.
Douglas M SprouleAveXis, Inc, Bannockburn, IL, USA. dsproule216@avexis.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Muscular Atrophy, SpinalOligonucleotidesHumansInfantnusinersenOligonucleotidesAVXS-101Indirect treatment comparisonNeuroscienceNusinersenOnasemnogene abeparvovecSpinal muscular atrophy type 1 (SMA type 1)

Identifiers

PMID31512141
PMCPMC6822794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.